Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma

Paul Harker-Murray • 4 Jun 2023
ASCO 2023
Hodgkin Lymphoma Lymphoma Antibodies Bendamustine Brentuximab vedotin Nivolumab

Paul Harker-Murray, MD, PhD, Medical College of Wisconsin, Milwaukee, WI, comments on the results of a study that evaluated nivolumab and brentuximab vedotin with or without bendamustine in patients with relapsed/refractory (R/R) Hodgkin Lymphoma (HL) at low risk of relapse. Dr Harker-Murray explains that this regimen was highly efficacious, suggesting that this subgroup of patients can be cured without autologous transplantation. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Paul Harker-Murray

2:44
CheckMate 744: response-adapted therapy without autoSCT in pediatric low-risk R/R cHL
Paul Harker-Murray • 4 Jun 2023

Related Videos

3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
1:32
Promising novel immunotherapeutic approaches in lymphoma
Gloria Iacoboni • 15 Apr 2024
3:03
AlloSCT outcomes after immunotherapy vs chemotherapy in patients with R/R NHL: a retrospective study
Jacopo Mariotti • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals